Patient characteristics
| Characteristic . | 10-d decitabine (n = 72) . | 10-d decitabine + ibrutinib (n = 72) . |
|---|---|---|
| Sex, male/female | 47/25 (65/35) | 42/30 (58/42) |
| Age, median (range), y | 76 (68-84) | 75 (66-89) |
| WHO performance | ||
| WHO 0 | 26 (36) | 25 (35) |
| WHO 1 | 38 (53) | 35 (49) |
| WHO 2 | 8 (11) | 12 (17) |
| Comorbidity | ||
| HCT-CI 0-2 | 42 (58) | 42 (58) |
| HCT-CI ≥3 | 30 (42) | 30 (42) |
| ELN risk group (AML) | ||
| Favorable | 15 (21) | 10 (14) |
| Intermediate | 12 (17) | 11 (15) |
| Adverse | 34 (47) | 37 (51) |
| Unknown | 0 (0) | 2 (3) |
| Primary AML | 48 (67) | 45 (63) |
| Secondary AML | 13 (18) | 15 (21) |
| MDS | 11 (15) | 12 (17) |
| WBC, median (range), ×109/L | 2.95 (0.70-29.9) | 3.20 (0.60-30.0) |
| Characteristic . | 10-d decitabine (n = 72) . | 10-d decitabine + ibrutinib (n = 72) . |
|---|---|---|
| Sex, male/female | 47/25 (65/35) | 42/30 (58/42) |
| Age, median (range), y | 76 (68-84) | 75 (66-89) |
| WHO performance | ||
| WHO 0 | 26 (36) | 25 (35) |
| WHO 1 | 38 (53) | 35 (49) |
| WHO 2 | 8 (11) | 12 (17) |
| Comorbidity | ||
| HCT-CI 0-2 | 42 (58) | 42 (58) |
| HCT-CI ≥3 | 30 (42) | 30 (42) |
| ELN risk group (AML) | ||
| Favorable | 15 (21) | 10 (14) |
| Intermediate | 12 (17) | 11 (15) |
| Adverse | 34 (47) | 37 (51) |
| Unknown | 0 (0) | 2 (3) |
| Primary AML | 48 (67) | 45 (63) |
| Secondary AML | 13 (18) | 15 (21) |
| MDS | 11 (15) | 12 (17) |
| WBC, median (range), ×109/L | 2.95 (0.70-29.9) | 3.20 (0.60-30.0) |
Data are n (%) except as noted.